MARK HUTTO: Open Payments
NPI 1699844159 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,818 in 13 payments from 8 companies in 2025. Trend: 2023 $502 · 2024 $306 · 2025 $4,818
Debt forgiveness: $4,575Food & beverage: $243
| Company | Payments | Amount |
|---|---|---|
| Neuronetics, Inc. | 1 | $4,575 |
| E.R. Squibb & Sons, L.L.C. | 4 | $85 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| Lundbeck LLC | 1 | $30 |
| Neurocrine BioSciences, Inc. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
Products named: NEUROSTAR TMS THERAPY SYSTEM, COBENFY, ABILIFY ASIMTUFII, CAPLYTA, INGREZZA, INVEGA SUSTENNA, UZEDY.
Industry payments across GA — which companies pay providers there.
